Hormone therapeutics increases woman cancered risk

According to on March 5 " periodical of American medicine association " (JAMA) go up along with visit research to point out, regard some as the one part of clinical trial, after the woman is stopping to take estrogen to add the hormone therapeutics of progesterone, they and the woman photograph that comfort agent group are compared, former meet with cancered risk may increase.

　　 is occupied on March 5 " periodical of American medicine association " (JAMA) go up along with visit research to point out, regard some as the one part of clinical trial, after the woman is stopping to take estrogen to add the hormone therapeutics of progesterone, they and the woman photograph that comfort agent group are compared, former meet with cancered risk may increase. The happening of these two groups of people the venture of cardiovascular disease and fracture is similar, but the index of overall and integrated risk that accepts hormone therapeutics woman is higher, this is in a lot of including that die to balance a relation to go up to combine terminal advantages and disadvantages to receive report.

Health of 　 　 woman contrives case (WHI) the woman after 6608 10 thousand menopause including in the test that estrogen imposes progesterone, these women are evaluated to accept conjugate estrogen (CEE) adds armour progesterone (whether can the cure of MPA) prevent heart disease and hipbone fracture, whether can the risk that reachs its meet with to contract breast cancer increase. This experiment stopped 2002, because the data at that time shows, the risk that this therapeutics can increase meet with to contract breast cancer and this therapeutics did not show the health of substantially benefits. Further analysis shows, the woman that CEE adds MPA treatment group has taller meet with to contract cardiovascular disease (CVD) , coronary heart disease (CHD) , apoplectic the risk that reachs disease of sex of vein thrombus embolism, and the risk that its meet with contracts fracture and colonic rectum cancer is inferior.

There were the risk that bears the person that try along with what visit and advantage to undertake examining at arriving in July 2002 between March 2005 after the GerardoHeiss that north of 　 　 United States blocks Luo Laina university and its colleague attend a trial to 5730 10 thousand and stopping hormone treatment.

Researcher discovers 　 　 , those stop hormone treatment (CEE adds MPA) along with visit the " that gets group of the person that try of consequence of all cancer " compare those who comfort agent group to suffer the person that try to want by occurence rate of year calculative incident tall (annual 1.56%[n=281] is opposite at annual 1.26%[n=218] ) . This mirrorred CEE to add MPA group to have taller meet with to have the risk of breast cancer of the sex that invade embellish and other cancer, the incidence of a disease of these two groups colonic rectum cancer does not have notable difference, but the incidence of a disease of cancer of the film inside the uterus adds MPA group in CEE inferior. Although be in,follow during visitting, these risks that bear meet with of the person that try to contract breast cancer still are in the condition of heighten, but this one risk is lower than wanting before experiment phases is about to end.

　 　 author writes in the article: "The optimal application CEE of the woman after adding MPA group to be menopause at comforting the analysis of the defer of agent group and durative advantages and disadvantages relatively to random distributive CEE added MPA to add new information. After stopping CEE to add MPA therapeutics [average] in process of 2.4 years, we observed the rapid change of the advantages and disadvantages related to hormone therapeutics, and follow the defer effect that visits the likelihood that will increase MPA to CEE to provide useful information to what this experiment participator undertakes persistent. After stopping use CEE to add MPA 3.5 in 8.5 years, look worth while still higher to the abidance that these disease suffer from malignant tumor risk keeps clinical the vigilance that go up. Look worth while still higher to the abidance that these disease suffer from malignant tumor risk keeps clinical the vigilance that go up..